Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $457,617.39 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 30,941 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $14.79, for a total value of $457,617.39. Following the completion of the transaction, the chief operating officer owned 647,809 shares in the company, valued at $9,581,095.11. This represents a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Julie Rubinstein also recently made the following trade(s):

• On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.68, for a total value of $285,672.80.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total transaction of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total transaction of $495,056.00.

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock traded down $0.43 during mid-day trading on Tuesday, hitting $14.52. 1,839,163 shares of the company’s stock were exchanged, compared to its average volume of 1,587,589. Adaptive Biotechnologies Corporation has a fifty-two week low of $6.26 and a fifty-two week high of $20.76. The company’s 50 day simple moving average is $16.72 and its 200-day simple moving average is $15.88.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. The business had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.Adaptive Biotechnologies’s quarterly revenue was up 51.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.23) EPS. On average, research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Institutional Trading of Adaptive Biotechnologies

Institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at approximately $28,000. Sound Income Strategies LLC acquired a new position in Adaptive Biotechnologies in the 3rd quarter valued at $30,000. EverSource Wealth Advisors LLC grew its holdings in shares of Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares in the last quarter. Assetmark Inc. raised its stake in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in Adaptive Biotechnologies during the fourth quarter worth about $51,000. Institutional investors own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

ADPT has been the subject of a number of analyst reports. Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price for the company. TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Guggenheim upped their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a report on Monday, January 26th. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a research note on Friday, February 6th. Finally, BTIG Research increased their price target on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.